Skip to main content

What the FDA labels say about taking them together

Imatinib and tafamidis

Tafamidis's FDA label of May 12, 2026 names imatinib in its drug interactions section; the imatinib labels PlainMeds reads (3) do not name tafamidis. The tafamidis label: “Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter and the risk of the substrate-related toxicities.”

Check it at the source: the imatinib FDA label on DailyMed (effective September 8, 2026, Apotex Corp); the tafamidis FDA label on DailyMed (effective May 12, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the imatinib label say about tafamidis?

Imatinib's label (effective September 8, 2026) and its 2 other brand-application labels do not name tafamidis in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Imatinib Mesylate), Apotex Corp, effective September 8, 2026 (SPL set 0291eca5-7a1d-4a79-30be-252224d96509), via openFDA; the full label on DailyMed

What does the tafamidis label say about imatinib?

Tafamidis label, drug interactions

Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities.

Source: FDA drug label (Vyndaqel), NDA211996 (Foldrx Pharms), as published by Pfizer Laboratories Div Pfizer Inc, effective May 12, 2026 (SPL set 1b4121ee-a733-4456-a917-be2603477839), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

20Imatinib generic labelers
0Tafamidis generic labelers
ImatinibTafamidis
Labeled forLeukemia, lymphoma and myeloman/a
Boxed warningNoNo
Pharmacy cost (NADAC)$0.624 per tablet 100 mg tabletn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?